

IMMUNOTEC INC. TO COMMENCE TRADING ON THE TSX VENTURE EXCHANGE

Montreal, January 23, 2007 - Following the successful completion of its reverse take-over of Magistral Biotech Inc., Immunotec Inc. ("Immunotec") is pleased to announce that the trading of its common shares through the facilities of the TSX Venture Exchange will commence at the opening of the market on January 24, 2007. Immunotec's common shares will trade under the symbol "IMM".

Shareholders of Immunotec are reminded that Letters of Transmittal have previously been mailed to them advising them as to the procedure to be followed in order to exchange the share or debenture certificates currently held by them, as applicable, for the share certificates newly adopted by Immunotec.

About Immunotec

Immunotec operates out of a 37,000 square foot facility located in Vaudreuil-Dorion, Quebec, Canada as well as a manufacturing facility located in Blainville, Quebec, Canada, and a distribution centre located in Swanton, Vermont, USA. Immunotec is engaged primarily in the development and marketing of dietary supplements, food, vitamins, personal care products and natural health products, some of which are manufactured on its behalf by third parties. Immunotec's products are distributed and sold in Canada and the United States through a network marketing system and in other countries under exclusive distributorship agreements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact: Richard Patte, Executive Vice-President and Chief
Financial Officer

Tel: 450-510-4445